NR1H4 and steatosis: In a randomized, placebo-controlled clinical trial, obeticholic acid (OCA; a synthetic FXR agonist) improved steatosis, inflammation, and fibrosis [40], indicating potential efficacy if used in the ex situ perfusion setting.